Media Articles Related to Reminyl (Galantamine)
Sleep disruption in Alzheimer's disease
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2014.02.28]
Being awake at night and dozing during the day can be a distressing early symptom of Alzheimer's disease, but how the disease disrupts our biological clocks to cause these symptoms has remained elusive.Now, scientists from Cambridge have discovered that in fruit flies with Alzheimer's the biological clock is still ticking but has become uncoupled from the sleep-wake cycle it usually regulates.
Earlier diagnosis of Alzheimer's disease through novel imaging technique
Source: MRI / PET / Ultrasound News From Medical News Today [2014.02.26]
New nuclear imaging techniques help in detecting Alzheimer's disease much earlier than before. Recently developed tracers, used with positron emission tomography (PET) make beta-amyloid in the brain visible. This part of a protein, which is a main causal factor of Alzheimer's, can now be detected long before the onset of the symptoms.
Targeting selected amyloid-beta dimers in early stages of Alzheimer's disease
Source: IT / Internet / E-mail News From Medical News Today [2014.02.21]
Researchers studying peptides using the Gordon supercomputer at the San Diego Supercomputer Center (SDSC) at the University of California, San Diego have found new ways to elucidate the creation of the toxic oligomers associated with Alzheimer's disease.
EnVivo Pharmaceuticals initiates COGNITIV AD, a Phase 3 clinical trial program of encenicline (EVP-6124) in Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.01.28]
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system (CNS) diseases, has announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (╬▒7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease (AD).
Brain repair after injury and Alzheimer's disease
Source: Rehabilitation / Physical Therapy News From Medical News Today [2013.12.27]
Researchers at Penn State University have developed an innovative technology to regenerate functional neurons after brain injury, and also in model systems used for research on Alzheimer's disease. The scientists have used supporting cells of the central nervous system, glial cells, to regenerate healthy, functional neurons, which are critical for transmitting signals in the brain.
Published Studies Related to Reminyl (Galantamine)
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. 
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment... Treatment was generally safe and well tolerated.
Galantamine improves sustained attention in chronic cocaine users. 
Chronic cocaine users are known to have cognitive deficits that are predictive of
poor treatment response. Whether these deficits improve with medications
targeting specific cognitive functions has not been examined in previous studies.
Clinical Trials Related to Reminyl (Galantamine)
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL«) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine
hydrobromide (REMINYL«) in patients with Alzheimer's disease who have not received or have
not responded to treatment with medication similar to galantamine hydrobromide (REMINYL«).
Effects of Galantamine on Cognition [Recruiting]
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early
twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
Such cognitive impairments and negative symptoms but much milder are also observed in
high-risk groups (such as relatives of schizophrenia patients), who may or may not develop
the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test
the effects of galantamine on clinical/physiological/cognitive measures. This study serves
several goals: If a drug is found effective in treating subtle deficits, then it will
provide treatment strategy in individuals with schizophrenia spectrum personality disorders
and for early intervention in schizophrenia. In addition, one of the difficulties of
testing a drug on schizophrenia is that patients take other medications (i. e., antipsychotic
drugs) that can change the effects of the test drug. The proposed study will be in subjects
who will not be taking antipsychotic medications. Our study will be carried out in two
sessions, at least one month apart. Subjects will be randomly assigned to the two possible
order of administration: the drug and then placebo, or the placebo and then drug. Subjects
will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8
mg (or placebo) on the 4th day, the day of testing. We will administer a battery of
clinical/cognitive/neurophysiological tests after the 8 mg drug dose.
A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is
to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and
Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl´┐Ż) [Recruiting]
Alzheimer's disease (AD) is characterized by progressive subcortical and cortical neuronal
degeneration. AD patients differ in the time course of neuronal degeneration and
accompanying cognitive decline.
With recent advances in MR imaging, including optimized data acquisition and processing
techniques, tools that are especially well suited for tracking long-term pathological
changes as well as drug treatment effects have become available. In addition to structural
imaging, new acquisition and analysis techniques have been developed to determine integrity
of subcortical fiber tracts in vivo.
In the present project we propose to determine predictors of disease progression and
treatment response and investigate potential treatment effects on structural disease
progression, covering the continuum from axonal degeneration to cortical neuronal loss
taking advantage of recent advances in MRI acquisition and analysis techniques.